AEterna Zentaris (AEterna Zentaris) Debt-to-EBITDA : -0.01 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AEterna Zentaris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.16 Mil. AEterna Zentaris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.12 Mil. AEterna Zentaris's annualized EBITDA for the quarter that ended in Dec. 2023 was $-25.41 Mil. AEterna Zentaris's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AEterna Zentaris's Debt-to-EBITDA or its related term are showing as below:

AEZS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1 Med: -0.02 Max: -0.01
Current: -0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of AEterna Zentaris was -0.01. The lowest was -0.10. And the median was -0.02.

AEZS's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs AEZS: -0.02

AEterna Zentaris Debt-to-EBITDA Historical Data

The historical data trend for AEterna Zentaris's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Debt-to-EBITDA Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.10

-0.05

-0.02

-0.01

-0.02

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.01	-0.01	-0.02	-0.01	-0.01

Competitive Comparison of AEterna Zentaris's Debt-to-EBITDA

For the Biotechnology subindustry, AEterna Zentaris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Debt-to-EBITDA falls into.

AEterna Zentaris Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AEterna Zentaris's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.16	+	0.119)	/	-17.839
	=	-0.02

AEterna Zentaris's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.16	+	0.119)	/	-25.412
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

AEterna Zentaris (NAS:AEZS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

AEterna Zentaris Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.